Biofunctionalized Magnetic Nanoparticles for Specifically Detecting Biomarkers of Alzheimer's Disease in Vitro
Biofunctionalized Magnetic Nanoparticles for Specifically Detecting Biomarkers of Alzheimer's Disease in Vitro
复制标题
DOI：
10.1021/cn200028j
复制
发表时间：
2011-09-01
影响因子：
5
通讯作者：
Chiu, Ming-Jang
中科院分区：
文献类型：
--
作者：
Yang, Che-Chuan;Yang, Shieh-Yueh;Chiu, Ming-Jang
合成了具有针对β-淀粉样蛋白-40（A β-40）和A β-42的抗体的生物功能化的磁性纳米颗粒，所述抗体是与阿尔茨海默病（AD）相关的有希望的生物标志物。我们表征了与抗A β抗体缀合的磁性纳米颗粒的尺寸分布、饱和磁化强度和稳定性。结合免疫磁性还原技术，证明了这种生物功能化的磁性纳米颗粒能够特异性地标记A β。使用磁性纳米颗粒通过免疫磁性还原在体外测定A β的超低检测限被确定为类似于10 ppt（10 pg/mL）的浓度。此外，分析了正常样品和AD患者的人血浆中A β-40和A β-42的免疫磁性还原信号，结果显示这两组之间存在显著差异。这些结果表明，使用磁性纳米粒子与A β s作为试剂的可行性，通过免疫磁性还原测定低浓度的A β s，也提供了一个有前途的新方法，从人血浆中早期诊断阿尔茨海默病。
Magnetic nanoparticles biofunctionalized with antibodies against beta-amyloid-40 (A beta-40) and A beta-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-A beta antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label A beta s specifically. The ultralow-detection limits of assaying A beta s in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of similar to 10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of A beta-40 and A beta-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with A beta s as reagents for assaying low-concentration A beta s through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.